Table 3.

Effectiveness of two treatments.

	Active device			Placebo device
	Pre	Post	p value	Pre	Post	p value
	Mean (±SD)	Mean (±SD)		Mean (±SD)	Mean (±SD)
Velocity (m/s)*	0.70 (0.25)	0.75 (0.23)	0.006	0.73 (0.22)	0.72 (0.25)	0.459
Stride length R (m)*	0.85 (0.25)	0.91 (0.24)	0.003	0.87 (0.21)	0.86 (0.2)	0.123
Stride length L (m)*	0.84 (0.16)	0.89 (0.25)	0.005	0.87 (0.25)	0.86 (0.26)	0.215
Stance R (%)*	64.8 (3.4)	63.6 (3.6)	0.026	63.6 (4.3)	64.6 (6.7)	0.352
Stance L (%)*	64.7 (2.9)	63.7 (4.1)	0.040	63.9 (4.1)	64.3 (8.1)	0.435
DST R (%)*	14.2(3.9)	13.3 (3.5)	0.036	14.9 (4.0)	14.2 (3.9)	0.472
DST L (%)*	14.7 (3.7)	13.8 (3.1)	0.007	14.8 (4.7)	14.4 (4.1)	0.543
UPDRS III TOTAL SCORE **	32.57 (15.4)	27.25 (12.0)	0.000°	31.87 (12.1)	28.85 (12.9)	0.005°
ITEM 3.10**	1.525 (0.96)	1.275 (0.78)	0.016°	1.550 (0.87)	1.359 (0.90)	0.130
ITEM 3.11**	0.500 (0.94)	0.500 (0.94)	1.00	0.650 (0.97)	0.447 (0.79)	0.153
ITEM 3.12**	1.400 (1.05)	1.025 (1.02)	0.009°	1.375 (1.03)	1.150 (1.02)	0.134
ITEM 3.13**	1.601 (1.17)	1.250 (1.03)	0.046	1.450 (1.19)	1.350 (1.18)	0.099

^*, ANOVA for repeated measures;

^**, p-value. Wilcoxon test with MC method IC 99%; °, upper limit of the confidence interval of p < 0.050.